Three doors, no borrowed ending
Phase 3 registry checkpoint · October 20, 2026
What are the next trials actually asking?
At the end of the corridor, Subject One finds three doors and three unfinished books. He reaches for a stamp marked SUCCESS. Doctide quietly replaces it with a bookmark. “We can mark where we are,” he says. “We cannot write the ending.” The visitor leaves all three books open.
What changes here
Three phase 3 studies are listed as recruiting. None has posted results; a registry entry is not an approval. [1] [2] [3]
Read the study details & dates
A shared design, separate populations
All three randomized, masked phase 3 studies compare a weekly subcutaneous petrelintide drug-device product with matching placebo alongside lifestyle measures. Each lists percentage weight change at week 64 as a primary endpoint. Their enrollment figures are estimates, not numbers already treated. [1] [2] [3]
Without type 2 diabetes
Estimated enrollment: 3,900 adults with obesity or overweight with a qualifying comorbidity, without type 2 diabetes. Recruiting; actual start September 30, 2026. No posted results. [1]
With type 2 diabetes
Estimated enrollment: 600 adults with overweight/obesity and type 2 diabetes. Recruiting; the September 30, 2026 start remains labeled estimated in this registry record. No posted results. [2]
With established cardiovascular disease
Estimated enrollment: 2,500 adults with overweight/obesity and established cardiovascular disease. Recruiting; actual start September 30, 2026. No posted results. Having cardiovascular disease in the population does not establish that the medicine prevents heart attacks or deaths. [3]
What this does not establish
No benefit, serious-harm rate or causality assessment can be invented for these ongoing studies. Protocol dates and recruitment can change. Patient One observes the evidence; he is not enrolled in any trial.
Original sources
- ClinicalTrials.gov — NCT07843498, ZUPREME-3; registry updated October 7, 2026
- ClinicalTrials.gov — NCT07843485, ZUPREME-4; registry updated October 7, 2026
- ClinicalTrials.gov — NCT07843472, ZUPREME-5; registry updated October 7, 2026
- Zealand Pharma — current petrelintide pipeline page; investigational status (sponsor source)
ClinicalTrials.gov API records and sponsor investigational-status page reviewed October 20, 2026. Phase 3 registry updates were posted October 7; no study results were posted.
Journal update record
2026-10-20 · Opened six linked chapters: laboratory design, rat body-composition research, completed phase 1 trials, published ZUPREME-1 including serious harms, sponsor-reported ZUPREME-2, and dated phase 3 registry checkpoints. Fiction remains separate from evidence.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story